The BioCapital region is a hub for biotechnology innovation, with significant growth in the past few decades. Within the groundbreaking field of cell therapy, we see an impressive 28 cell & gene therapy companies headquartered in the region, each with at least an active cell and/or gene therapy program in our BiopharmIQ database. Maryland boasts the highest concentration of cell therapy company headquarters (FIG. 1 📷).
![](https://static.wixstatic.com/media/5decac_9f17124e505a49cd8493c40fa9b4f75c~mv2.gif)
FIG. 1. BioCapital Biopharma Companies.
____________________________________________________________________________________________
Representative Company Snapshots
Sirnaomics (HKG: 2257)
Status: Public
Location: Gaithersburg, MD
Technologies: RNA-based therapeutics
Overview: Sirnaomics is developing RNA-based therapeutics for Cancer, Hematologic, infectious diseases, and others. STP705 is their lead drug candidate, a dual TGF-ß1 & COX-2 inhibitor which are well-validated gatekeeper targets for oncology and fibrosis disease drug development.
Cartesian Therapeutics (NASDAQ: RNAC)
Status: Public
Location: Gaithersburg, MD
Technologies: mRNA cell therapeutics
Overview: a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis.
Virion Therapeutics
Status: Private
Location: Newark, DE
Technologies: T-cell immunotherapeutics
Overview: a clinical-stage company developing novel T cell-based immunotherapies for cancer and chronic infectious diseases. VRON-0200 is the company's most advanced therapeutic candidate which treats chronic HBV infection and is currently in Ph1 clinical trials.
Are you a CRO, CMO, or Biopharma vendor? Get a list of 100's of biopharma companies with cell therapy products. Perfect for sales and business development activities. Access our free report here: https://www.biopharmiq.com/cell-therapy-companies-report
Article History
Original published: 03/13/24 RF
This article is not investment or legal advice.
Comments